Total Payments
$237,803
2024 Payments
$6,978
Companies
22
Transactions
429
Medicare Patients
7,779
Medicare Billing
$887,008
Payment Breakdown by Category
Other$126,602 (53.2%)
Research$68,404 (28.8%)
Consulting$23,045 (9.7%)
Travel$10,533 (4.4%)
Food & Beverage$9,107 (3.8%)
Education$110.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $124,272 | 54 | 52.3% |
| Unspecified | $68,404 | 11 | 28.8% |
| Consulting Fee | $23,045 | 10 | 9.7% |
| Travel and Lodging | $10,533 | 44 | 4.4% |
| Food and Beverage | $9,107 | 303 | 3.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,330 | 1 | 0.6% |
| Grant | $1,000 | 1 | 0.4% |
| Education | $110.95 | 5 | 0.0% |
Payments by Type
General
$169,399
418 transactions
Research
$68,404
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $112,518 | 150 | $0 (2022) |
| Fisher & Paykel Healthcare Limited | $68,404 | 11 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $28,675 | 61 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $17,116 | 31 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $3,211 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,107 | 5 | $0 (2019) |
| Genentech USA, Inc. | $1,455 | 1 | $0 (2021) |
| Inspire Medical Systems, Inc. | $1,284 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,277 | 120 | $0 (2023) |
| Genentech, Inc. | $1,000 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,978 | 27 | JAZZ PHARMACEUTICALS INC. ($5,874) |
| 2023 | $19,267 | 40 | JAZZ PHARMACEUTICALS INC. ($11,006) |
| 2022 | $4,368 | 20 | AstraZeneca Pharmaceuticals LP ($3,437) |
| 2021 | $17,725 | 53 | AstraZeneca Pharmaceuticals LP ($11,601) |
| 2020 | $8,497 | 31 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,046) |
| 2019 | $36,466 | 73 | Boehringer Ingelheim Pharmaceuticals, Inc. ($34,203) |
| 2018 | $36,096 | 98 | Boehringer Ingelheim Pharmaceuticals, Inc. ($27,600) |
| 2017 | $108,404 | 87 | Fisher & Paykel Healthcare Limited ($68,404) |
All Payment Transactions
429 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $32.00 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $20.10 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,517.00 | General |
| Category: NEUROLOGY | ||||||
| 11/12/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $32.72 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $74.99 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: NEUROLOGY | ||||||
| 10/09/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $1.72 | General |
| Category: NEUROLOGY | ||||||
| 10/08/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: NEUROLOGY | ||||||
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $127.93 | General |
| Category: Respiratory | ||||||
| 09/25/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $153.30 | General |
| Category: NEUROLOGY | ||||||
| 09/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Respiratory | ||||||
| 09/03/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $7.68 | General |
| Category: NEUROLOGY | ||||||
| 07/19/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: NEUROLOGY | ||||||
| 06/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $57.66 | General |
| Category: NEUROLOGY | ||||||
| 06/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: NEUROLOGY | ||||||
| 06/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: NEUROLOGY | ||||||
| 06/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: NEUROLOGY | ||||||
| 05/20/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Education | In-kind items and services | $41.50 | General |
| Category: NEUROLOGY | ||||||
| 05/02/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: Respiratory | ||||||
| 04/25/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| Category: Narcoplepsy | ||||||
| 03/29/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $79.60 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The Evaluation of a full face and nasal mask | Fisher & Paykel Healthcare Limited | $15,646 | 2 |
| Clinical Study | Fisher & Paykel Healthcare Limited | $15,046 | 2 |
| Clinical Trial | Fisher & Paykel Healthcare Limited | $9,448 | 2 |
| Respiratory | Fisher & Paykel Healthcare Limited | $9,448 | 2 |
| Research | Fisher & Paykel Healthcare Limited | $8,543 | 1 |
| Evaluation of a Full-Face Mask | Fisher & Paykel Healthcare Limited | $7,330 | 1 |
| Clinical Trials | Fisher & Paykel Healthcare Limited | $2,945 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,536 | 2,927 | $900,492 | $264,614 |
| 2022 | 18 | 2,177 | 2,519 | $780,229 | $228,795 |
| 2021 | 15 | 1,803 | 2,078 | $722,567 | $222,873 |
| 2020 | 13 | 1,263 | 1,453 | $652,359 | $170,726 |
Total Patients
7,779
Total Services
8,977
Medicare Billing
$887,008
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 570 | 728 | $93,755 | $46,392 | 49.5% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 88 | 89 | $194,800 | $41,375 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 237 | 305 | $80,875 | $39,441 | 48.8% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 63 | 65 | $156,000 | $31,795 | 20.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 343 | 343 | $95,697 | $27,765 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 193 | $36,907 | $18,290 | 49.6% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 133 | 244 | $108,361 | $16,123 | 14.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 63 | 63 | $24,012 | $10,317 | 43.0% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 342 | 353 | $24,713 | $10,015 | 40.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 105 | 105 | $12,015 | $4,185 | 34.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $9,339 | $3,941 | 42.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 144 | 148 | $12,284 | $3,743 | 30.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 74 | 74 | $12,210 | $3,049 | 25.0% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 29 | 29 | $14,819 | $2,949 | 19.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 82 | 82 | $10,580 | $2,371 | 22.4% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 19 | 33 | $11,016 | $1,565 | 14.2% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 21 | 21 | $1,219 | $677.19 | 55.5% |
| 95976 | Electronic analysis of neurostimulator generator with simple cranial nerve stimulator programming | Office | 2023 | 20 | 21 | $1,890 | $621.40 | 32.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 495 | 629 | $81,632 | $40,259 | 49.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 80 | 80 | $174,306 | $37,969 | 21.8% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 61 | 67 | $160,800 | $33,238 | 20.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 354 | 354 | $98,766 | $28,415 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 160 | 205 | $54,735 | $27,494 | 50.2% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2022 | 93 | 185 | $80,222 | $11,652 | 14.5% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 347 | 376 | $25,792 | $11,053 | 42.9% |
About Dr. David Ostransky, D.O
Dr. David Ostransky, D.O is a Pulmonary Disease healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396710984.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ostransky, D.O has received a total of $237,803 in payments from pharmaceutical and medical device companies, with $6,978 received in 2024. These payments were reported across 429 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($124,272).
As a Medicare-enrolled provider, Ostransky has provided services to 7,779 Medicare beneficiaries, totaling 8,977 services with total Medicare billing of $887,008. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Sleep Medicine
- Location Fort Worth, TX
- Active Since 02/17/2006
- Last Updated 10/23/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1396710984
Products in Payments
- BREZTRI (Drug) $22,577
- XYWAV (Drug) $17,004
- SPIRIVA RESPIMAT (Drug) $5,144
- FASENRA (Drug) $4,981
- DUPIXENT DUPILUMAB INJECTION (Biological) $3,194
- STIOLTO RESPIMAT (Drug) $3,165
- Xolair (Biological) $1,455
- SPIRIVA (Drug) $923.99
- INSPIRE (Device) $838.24
- Inspire Upper Airway Stimulation System (Device) $446.11
- NUCALA (Biological) $368.79
- FEVIPIPRANT (Drug) $348.42
- TRELEGY ELLIPTA (Drug) $301.42
- SYMBICORT (Drug) $264.81
- AIRSUPRA (Drug) $247.93
- The Vest System Model 105 Home Care (Device) $237.92
- ANORO (Drug) $220.83
- TEZSPIRE (Biological) $210.65
- FASENRA (Biological) $191.20
- BREO (Drug) $187.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Fort Worth
Sherif Al-Farra, Md, MD
Pulmonary Disease — Payments: $70,511
Pulmonary Disease $70,511
Sai Karan Vamsi Guda, D.o, D.O
Pulmonary Disease — Payments: $33,705
Pulmonary Disease $33,705
John Burk, Md, MD
Pulmonary Disease — Payments: $17,590
Pulmonary Disease $17,590
Lavanya Srinivasan, M.d, M.D
Pulmonary Disease — Payments: $2,329
Pulmonary Disease $2,329
Abigale Henry, M.d, M.D
Pulmonary Disease — Payments: $1,743
Pulmonary Disease $1,743
Dr. Vikas Goyal, Md, MD
Pulmonary Disease — Payments: $1,119
Pulmonary Disease $1,119